What sedative is recommended after rapid sequence intubation (RSI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Sedatives After Rapid Sequence Intubation

After rapid sequence intubation (RSI), a sedative-hypnotic agent should always be administered to maintain sedation, with options including midazolam, propofol, or ketamine based on the patient's hemodynamic status. 1

Key Recommendations for Post-RSI Sedation

General Principles

  • A sedative-hypnotic agent must be administered after RSI to prevent awareness during paralysis, which occurs in approximately 2.6% of emergency intubations 1, 2
  • Timely administration of post-intubation sedation is critical, especially when long-acting paralytics like rocuronium are used 3
  • Sedation should be initiated promptly after intubation, with median time to first dose typically being 10-12 minutes 3

Specific Sedative Options

For Hemodynamically Stable Patients:

  • Propofol:
    • Initial infusion rate of 20-30 μg/kg/min (can be titrated up as needed) 3
    • Benefits: Rapid onset, short duration, easily titratable 4
    • Caution: May cause hypotension; use lower doses in elderly or debilitated patients 4

For Hemodynamically Unstable Patients:

  • Ketamine:

    • Dose: 1-2 mg/kg IV bolus followed by 0.5-1 mg/kg/hr infusion 2
    • Benefits: Maintains hemodynamic stability through sympathomimetic properties 2
    • Particularly valuable in shock states 2
  • Midazolam:

    • Dose: 0.01-0.05 mg/kg IV bolus (approximately 0.5-4 mg) followed by 0.02-0.10 mg/kg/hr infusion 5
    • Reduce dose by 25-50% in elderly, critically ill, or hemodynamically unstable patients 5
    • Benefits: Amnestic properties, relatively stable hemodynamic profile compared to propofol 5

Important Considerations

Timing of Sedation

  • Patients receiving rocuronium are at higher risk of delayed sedation (median 12 minutes) compared to those receiving succinylcholine (median 10 minutes) 3
  • The presence of a pharmacist during intubation is associated with improved timely administration of sedation (adjusted hazard ratio 1.14) 3

Hemodynamic Considerations

  • Post-intubation hypotension is common and associated with increased mortality, prolonged ICU stays, and organ dysfunction 1
  • Hypotension after intubation is predictive of decreased sedation administration (adjusted hazard ratio 0.67) 3
  • For patients with hemodynamic instability, ketamine may be preferred over propofol due to its sympathomimetic effects 2

Dosing Adjustments

  • Lower initial doses (25-50% reduction) should be used in elderly patients, those with severe systemic disease, or hemodynamic instability 5
  • Titrate to the desired level of sedation by adjusting infusion rates up or down by 25-50% 5
  • Find the minimum effective infusion rate to avoid drug accumulation and facilitate faster recovery 5

Common Pitfalls to Avoid

  • Delaying sedation after RSI, especially with long-acting paralytics like rocuronium, which increases risk of awareness during paralysis 3
  • Using inadequate initial doses of sedatives (median post-RSI propofol infusion rates are often too low at 20 μg/kg/min) 3
  • Failing to adjust sedation requirements based on the patient's hemodynamic status 1
  • Not providing concurrent analgesia, which should be administered within 21-24 minutes after intubation 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Rapid Sequence Intubation with Succinylcholine, Ketamine, and Midazolam

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Impact of paralytic choice on postintubation sedation and analgesia in the emergency department.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.